Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Ritz

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
AIDS (London, England)|April 8, 2021
Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settingsTanakorn Apornpong, Beatriz Grinsztejn, Michael Hughes, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical TrialKara W Chew, Carlee Moser, Eric S Daar, et al.
The Journal of Infectious Diseases|May 8, 2024
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2Manish C Choudhary, Rinki Deo, Teresa H Evering, et al.
Nature Communications|August 22, 2022
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 studyEvelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Nature Communications|January 19, 2023
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Pathogens & Immunity|May 20, 2026
Impact of Sex on Viral Shedding and Symptom Severity During Acute COVID-19Evelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Medrxiv : the Preprint Server for Health Sciences|January 12, 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infectionJulie Boucau, Kara W Chew, Manish Choudhary, et al.
Cell Reports. Medicine|July 6, 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infectionJulie Boucau, Kara W Chew, Manish C Choudhary, et al.
Annals of Internal Medicine|April 17, 2023
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19Teresa H Evering, Kara W Chew, Mark J Giganti, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
AIDS (London, England)|April 8, 2021
Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settingsTanakorn Apornpong, Beatriz Grinsztejn, Michael Hughes, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical TrialKara W Chew, Carlee Moser, Eric S Daar, et al.
The Journal of Infectious Diseases|May 8, 2024
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2Manish C Choudhary, Rinki Deo, Teresa H Evering, et al.
Nature Communications|August 22, 2022
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 studyEvelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Nature Communications|January 19, 2023
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Pathogens & Immunity|May 20, 2026
Impact of Sex on Viral Shedding and Symptom Severity During Acute COVID-19Evelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Medrxiv : the Preprint Server for Health Sciences|January 12, 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infectionJulie Boucau, Kara W Chew, Manish Choudhary, et al.
Cell Reports. Medicine|July 6, 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infectionJulie Boucau, Kara W Chew, Manish C Choudhary, et al.
Annals of Internal Medicine|April 17, 2023
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19Teresa H Evering, Kara W Chew, Mark J Giganti, et al.
Pageof 6